scholarly journals Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review

2009 ◽  
Vol 13 (5) ◽  
Author(s):  
P Sutcliffe ◽  
S Hummel ◽  
E Simpson ◽  
T Young ◽  
A Rees ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Risk Factors ◽  
Systematic Review ◽  
Novel Biomarkers ◽  
Prognostic Risk Factors

scholarly journals MO27-2 Risk factors for metastasis in prostate cancer patients: A systematic review

2021 ◽  
Vol 32 ◽  
pp. S315
Author(s):  
Billy Susanto ◽  
Griffin Geraldo ◽  
Jennifer Jesse Limanto ◽  
Andree Kurniawan
Keyword(s):  
Prostate Cancer ◽  
Risk Factors ◽  
Systematic Review ◽  
Cancer Patients

Prostate cancer risk calculators for healthy population: A systematic review (Preprint)

2021 ◽  
Author(s):  
Antonio Bandala-Jacques ◽  
Kevin Daniel Castellanos Esquivel ◽  
Fernanda Pérez-Hurtado ◽  
Cristobal Hernández-Silva ◽  
Nancy Reynoso-Noverón
Keyword(s):  
Prostate Cancer ◽  
Risk Factors ◽  
Systematic Review ◽  
Cancer Risk ◽  
Digital Rectal Examination ◽  
Prostate Cancer Risk ◽  
Individual Risk ◽  
Healthy Population ◽  
Risk Of Cancer ◽  
The Impact

BACKGROUND Screening for prostate cancer has long been a debated, complex topic. The use of risk calculators for prostate cancer is recommended for determining patients’ individual risk of cancer and the subsequent need for a prostate biopsy. These tools could lead to a better discrimination of patients in need of invasive diagnostic procedures and for optimized allocation of healthcare resources OBJECTIVE To systematically review available literature on current prostate cancer risk calculators’ performance in healthy population, by comparing the impact factor of individual items on different cohorts, and the models’ overall performance. METHODS We performed a systematic review of available prostate cancer risk calculators targeted at healthy population. We included studies published from January 2000 to March 2021 in English, Spanish, French, Portuguese or German. Two reviewers independently decided for or against inclusion based on abstracts. A third reviewer intervened in case of disagreements. From the selected titles, we extracted information regarding the purpose of the manuscript, the analyzed calculators, the population for which it was calibrated, the included risk factors, and the model’s overall accuracy. RESULTS We included a total of 18 calculators across 53 different manuscripts. The most commonly analyzed ones were they PCPT and ERSPC risk calculators, developed from North American and European cohorts, respectively. Both calculators provided high precision for the diagnosis of aggressive prostate cancer (AUC as high as 0.798 for PCPT and 0.91 for ERSPC). We found 9 calculators developed from scratch for specific populations, which reached diagnostic precisions as high as 0.938. The most commonly included risk factors in the calculators were age, PSA levels and digital rectal examination findings. Additional calculators included race and detailed personal and family history CONCLUSIONS Both the PCPR and the ERSPC risk calculators have been successfully adapted for cohorts other than the ones they were originally created for with no loss of diagnostic accuracy. Furthermore, designing calculators from scratch considering each population’s sociocultural differences has resulted in risk tools that can be well adapted to be valid in more patients. The best risk calculator for prostate cancer will be that which was has been calibrated for its intended population and can be easily reproduced and implemented CLINICALTRIAL CRD42021242110

scholarly journals Epidemiology of prostate and kidney cancer in the Aboriginal population of Canada: A systematic review

2017 ◽  
Vol 11 (5) ◽  
pp. 222 ◽  
Author(s):  
Emily Chu Lee Wong ◽  
Anil Kapoor
Keyword(s):  
Prostate Cancer ◽  
Risk Factors ◽  
Systematic Review ◽  
Kidney Cancer ◽  
Statistical Significance ◽  
Survival Rates ◽  
Significant Finding ◽  
Aboriginal Population ◽  
Incidence And Mortality ◽  
Reported Data

Introduction: Prostate and kidney cancer rates in the Aboriginal population of Canada is a growing issue.Methods: A systematic review of prostate and kidney cancer epidemiology in the Aboriginal population of Canada was performed with international comparison and evaluation of present epidemiological disparities. PubMed, Medline, and Embase (from January 1946 to June 2016), relevant government-published reports, and the websites of organizations contributing to prostate or kidney cancer guidelines were searched. We included studies that informed any of the three epidemiological questions this review is focused on answering. Results: Two systematic reviews, two meta-analyses, five literature reviews, and 21 single-study papers were included. The incidence and mortality rates of kidney cancer were elevated among Canadian Aboriginals when compared to the provincial or national population and to several international regions. No studies reported data on survival. Prostate cancer incidence, mortality, and survival rates were lower in Aboriginals provincially, nationally, and internationally, with incidence and survival reaching statistical significance. Elevated rate of risk factors for kidney cancer was a significant finding among Canadian Aboriginals. Aboriginals were screened for prostate cancer less than the general Canadian population, a trend also observed in the U.S.Conclusions: The elevated incidence and mortality of kidney cancer among Canadian Aboriginals is most likely attributable to the rise in lifestyle-based risk factors. Two correlations concerning prostate cancer are made. However, due to temporal and regional disparities in data, further investigation is required to elucidate these observations.

scholarly journals Prostate Cancer Awareness Among Women: A Mixed-methods Systematic Review

2020 ◽  
Author(s):  
Ebenezer Wiafe ◽  
Kofi Boamah Mensah ◽  
Adwoa Bemah Boamah Mensah ◽  
Varsha Bangalee ◽  
Frasia Oosthuizen
Keyword(s):  
Prostate Cancer ◽  
Risk Factors ◽  
Systematic Review ◽  
Mixed Methods ◽  
Prostate Cancer Screening ◽  
Signs And Symptoms ◽  
Cost Effective ◽  
Cancer Awareness ◽  
Awareness Campaigns ◽  
Causes And Risk Factors

Abstract Background: With the burden of prostate cancer, it has become imperative to exploit cost-effective ways to tackle this menace. Women have demonstrated their ability to recognize early cancer signs and it is therefore relevant to include women in strategies to improve the early detection of prostate cancer. This systematic review seeks to gather evidence from studies that investigated women’s knowledge about; (1) the signs and symptoms, (2) causes and risk factors, and (3) the screening modalities of prostate cancer. Findings from the review will better position women in the fight against the late detection of prostate cancer.Methods: The convergent segregated approach to the conduct of mixed-methods systematic reviews was employed. Five databases namely; MEDLINE (EBSCOhost), CINAHL (EBSCOhost), PsycINFO (EBSCOhost), Web of Science, and EMBASE (Ovid) were searched from January 1999 to December 2019 for studies conducted with a focus on the knowledge of women on the signs and symptoms; the causes and risk factors; and the screening modalities of prostate cancer.Results: Of 2201 titles and abstracts screened, 22 full-text papers were retrieved and reviewed, and 7 were included: 3 quantitative, 1 qualitative, and 3 mixed-methods studies. Both quantitative and qualitative findings indicate that women have moderate knowledge of the signs and symptoms; and the causes and risk factors of prostate cancer. However, women recorded poor knowledge about prostate cancer screening modalities or tools.Conclusions: Moderate knowledge of women on the signs and symptoms, and the causes and risk factors of prostate cancer were associated with education. These findings provide vital information for the prevention and control of prostate cancer and encourage policy-makers to incorporate health promotion and awareness campaigns in health policies to improve knowledge and awareness of prostate cancer globally.Systematic Review registration number: Open Science Framework (OSF) registration DOI: https://doi.org/10.17605/OSF.IO/BR456

Circulating microRNAs as novel biomarkers in the diagnosis of prostate cancer: a systematic review and meta-analysis

2016 ◽  
Vol 48 (7) ◽  
pp. 1087-1095 ◽  
Author(s):  
Changqing Yin ◽  
Cheng Fang ◽  
Hong Weng ◽  
Chunhui Yuan ◽  
Fubing Wang
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Meta Analysis ◽  
Circulating Micrornas ◽  
Novel Biomarkers

A Systematic Review of the Incidence and Risk Factors for Taxane Acute Pain Syndrome in Patients Receiving Taxane-Based Chemotherapy for Prostate Cancer

2017 ◽  
Vol 15 (1) ◽  
pp. 1-6 ◽  
Author(s):  
Ricardo Fernandes ◽  
Sasha Mazzarello ◽  
Brian Hutton ◽  
Risa Shorr ◽  
Mohammed F.K. Ibrahim ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Risk Factors ◽  
Systematic Review ◽  
Acute Pain ◽  
Pain Syndrome

Prognostic role of docetaxel-induced reduction of free testosterone serum levels in metastatic prostate cancer patients.

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. 144-144
Author(s):  
Paula Kappler ◽  
Stefan Brunotte ◽  
Philipp Ivanyi ◽  
Michael A. Morgan ◽  
Christoph W. Reuter
Keyword(s):  
Prostate Cancer ◽  
Risk Factors ◽  
Cox Regression ◽  
Specific Antigen ◽  
Serum Levels ◽  
Prognostic Role ◽  
Cycle Number ◽  
Prognostic Risk Factors ◽  
The Impact

144 Background: We have recently demonstrated that a salvage therapy with carboplatin plus weekly docetaxel is effective in docetaxel-refractory prostate cancer (PC) and interferes with testosterone biosynthesis (Reuter et al.; Oncol Res & Treat. 2018, 41 (suppl.1): p.10). In this study, the impact of docetaxel monotherapy on free and total testosterone serum levels (fT, TT) and the prognostic role of fT and TT were analyzed in mPC patients. Methods: 62 consecutive mPC patients were treated with at least two cycles of docetaxel (75 mg/m2 q3w; 50 mg/m2 q2w, or 35 mg/m2 q1w) until disease progression, occurrence of intolerable adverse effects or completion of the planned cycle number. Efficacy measures were done following PCWG2 recommendations. FT and TT were measured before and during chemotherapy. Results: At the current analysis (August 31, 2020), the median follow-up time was 21.2 months. Response of prostate-specific antigen (PSAR; ≥50% PSA reduction) was observed in 42/62 (67.7%) and 12/36 (33.3%) patients with measurable disease exhibited a partial remission (PR). Median progression-free survival (PFS) for all patients was 8.1 months (CI 95% 3.6, 12.5) and median overall survival (OS) was 25.7 months (CI 95% 19.4, 32.1). The most common reversible grade 3/4 toxicity was leukopenia/neutropenia (29/33.9%). Median fT and TT serum levels were reduced below the detection limit during docetaxel treatment (fT: from 0.34 pg/mL to < 0.01 pg/mL and TT: from 0.12 to < 0.05 ng/mL, respectively). Multivariate Cox regression analyses identified PSAR > 50%, fT reduction of 100% and number of organs involved as independent prognostic risk factors for PFS. Furthermore, fT reduction of 100% and FT nadir values < 0.01 pg/mL were independent prognostic risk factors for OS (p < 0.05). Conclusions: These data demonstrate that fT is an important prognostic factor for PFS and OS in mPC patients.

214: Incidence and Risk Factors of Symptomatic DVT in Prostate Cancer Patients Undergoing Laparoscopic Radical Prostatectomy

2006 ◽  
Vol 175 (4S) ◽  
pp. 70-71
Author(s):  
Fernando P. Secin ◽  
Clément-Claude Abbou ◽  
Inderbir S. Gill ◽  
Georges Fournier ◽  
Thierry Piéchaud ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Risk Factors ◽  
Radical Prostatectomy ◽  
Cancer Patients ◽  
Laparoscopic Radical Prostatectomy
Sign in / Sign up

Export Citation Format

Share Document